Abstracts Archive - Page 1815 of 2607 - ACR Meeting Abstracts

Abstract Number: 3255 • 2016 ACR/ARHP Annual Meeting
A Randomized Trial of Automated Telephone-Linked Communication to Improve Exercise Adherence for a Progressive Resistance Training Program in People with Knee Osteoarthritis
Kristin Baker¹, Aileen Ledingham¹, Carrie Brown², Kelly Pesanelli³, Faye Cochrane⁴, Robert Friedman⁵, Michael P. LaValley⁶, David T. Felson⁷ and Julie J. Keysor^1,8, ¹Physical Therapy, Boston University Sargent College, Boston, MA, ²Boston University School of Public Health, Boston, MA, ³Health Sciences, Boston University Sargent College, Boston, MA, ⁴ENACT, Boston University Sargent College, Boston, MA, ⁵Boston University School of Medicine, Boston, MA, ⁶Biostatistics, Boston University School of Public Health, Boston, MA, ⁷Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ⁸Clinical Epidemiology Research and Training, Boston University School of Medicine, Boston, MA
Background/Purpose: In knee osteoarthritis (OA) strengthening exercise improves pain and physical function, however a marked decline in exercise adherence has limited the long term efficacy…
Abstract Number: 3256 • 2016 ACR/ARHP Annual Meeting
Functional Ability ‘to Rise’ and Autonomy Support for Physical Activity: Implications for Light Physical Activity Engagement and Psychological Wellbeing in People Living with Rheumatoid Arthritis
Sally Fenton^1,2, Jet Veldhuijzen van Zanten², George Metsios^2,3, Peter Rouse⁴, Chen-an Yu⁵, George D. Kitas^1,2 and Joan Duda¹, ¹School of Sport, Exercise and Rehabilitation, University of Birmingham, Birmingham, United Kingdom, ²Department of Rheumatology, Russells Hall Hospital, Dudley Group of Hospitals NHS Foundation Trust, Dudley, United Kingdom, ³Department of Physical Activity Exercise and Health, University of Wolverhampton, Walsall, United Kingdom, ⁴Department for Health, University of Bath, Bath, United Kingdom, ⁵School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham, Birmingham, United Kingdom
Background/Purpose: Epidemiological studies indicate participation in light physical activity (LPA) is positively associated with psychological wellbeing. For patients with Rheumatoid Arthritis (RA), reduced functional ability…
Abstract Number: 52 • 2016 ACR/ARHP Annual Meeting
Pregabalin Dose-Response for Sleep Quality and Pain Response in Fibromyalgia: A Post-Hoc Analysis of Three Randomized Trials
Andrew Clair¹, Ed Whalen¹, Neal Thomas¹ and Lynne Pauer², ¹Pfizer, New York, NY, ²Pfizer, Groton, CT
Background/Purpose: Pregabalin is often administered for treatment of fibromyalgia (FM) at daily doses lower than approved by the US Food and Drug Administration (starting dose…
Abstract Number: 53 • 2016 ACR/ARHP Annual Meeting
Efficacy of Cannabis Flos in Patients with Fibromyalgia: A Monocentric Observational Study
Maria Chiara Gerardi¹, Alberto Batticciotto², Rossella Talotta¹, Maria Chiara Ditto¹, Fabiola Atzeni² and Piercarlo Sarzi-Puttini¹, ¹Rheumatology Unit, ASST Fatebenefratelli - Sacco, L. Sacco University Hospital, Milan, Italy, ²Rheumatology Unit, ASST Fatebenefratelli - Sacco, L. Sacco University Hospital, Milano, Italy
Efficacy of Cannabis flos in patients with fibromyalgia: a monocentric observational study Background/Purpose: Fibromyalgia (FM) is a syndrome characterized by chronic widespread pain, fatigue,…
Abstract Number: 54 • 2016 ACR/ARHP Annual Meeting
Patients with Fibromyalgia in General Have Higher Self-Report Questionnaire Scores Than Patients with Rheumatoid Arthritis: Implications for Clinical Trials and Clinical Research
Theodore Pincus¹, Isabel Castrejón¹, Joel Block² and Nathaniel Cook¹, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Division of Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Patients with rheumatoid arthritis (RA) who are included in clinical trials generally are selected for measures indicating high disease activity, such as more than…
Abstract Number: 55 • 2016 ACR/ARHP Annual Meeting
Identification of Endogenous Autoantigens Bound to Anti-Citrullinated Peptide Antibodies in Rheumatoid Arthritis: A Key Role for Citrulline Residues in Histone 4
Xiaobo Meng¹, Peyman Ezzati¹, Irene Smolik², Carol Hitchon³ and Hani El-Gabalawy⁴, ¹UNIVERSITY OF MANITOBA, WINNIPEG, MB, Canada, ²Arthritis Center, University of Manitoba, Winnipeg, MB, Canada, ³University of Manitoba, Winnipeg, MB, Canada, ⁴University of Manitoba Arthritis Center, Winnipeg, MB, Canada
Background/Purpose: Anti-Citrullinated Peptides Antibodies (ACPA) aid in rheumatoid arthritis (RA) diagnosis. The nature of autoantigens specifically bound to ACPA immune complex in vivoremains unclear. We…
Abstract Number: 56 • 2016 ACR/ARHP Annual Meeting
A Systems Biology Approach to Investigating Beneficial Effects of Endurance Exercise in Myositis Patients
Jessica Boehler^1,2, Marshall Hogarth³, Matthew Barberio³, Svetlana Ghimbovschi², Kristy Brown^1,2, Li Alemo Munters⁴, Ingela Loell⁴, Yi-Wen Chen^2,5, Helene Alexanderson⁶, Ingrid E. Lundberg⁷ and Kanneboyina Nagaraju^5,8, ¹Department of Integrative Systems Biology, The George Washington University, Washingtion, DC, ²Research Center for Genetic Medicine, Children's National Medical Center, Washington, DC, ³Research Center for Genetic Medicine, Children's National Medical Center, Washingtion, DC, ⁴Karolinska University Hospital, Rheumatology Unit, Department of Medicine, Solna, Karolinska Institutet, Karolinska University Hospital, Sweden, Stockholm, Sweden, ⁵Department of Integrative Systems Biology, The George Washington University, Washington, DC, ⁶Department of NVS, Division of Physical Therapy, Karolinska Institutet, Huddinge, Sweden, ⁷Department of Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁸Research Center for Genetic Medicine, Children’s National Medical Center, Washington, DC
Background/Purpose: Polymyositis (PM) and dermatomyositis (DM) are skeletal muscle disorders characterized by proximal muscle weakness and inflammation. Recent studies have suggested that endurance exercise improves…
Abstract Number: 57 • 2016 ACR/ARHP Annual Meeting
Genetic Polymorphism of IL-1RN Encoding the IL-1 Receptor Antagonist Predicts Radiographic Severity of Symptomatic Knee OA
Mukundan Attur¹, Sisi Ma², Jonathan Samuels³, Svetlana Krasnokutsky Samuels⁴, Hua Zhou², Jenny Bencardino⁵, Marc C. Hochberg⁶, Braxton Mitchell⁷, Virginia B. Kraus⁸, Joanne M. Jordan⁹ and Steven B. Abramson¹⁰, ¹Rheumatology Research, NYU - Hospital for Joint Diseases, New York, NY, ²Bioinformatics, New York University, New York, NY, ³Rheumatology, NYU - Hospital for Joint Diseases, New York, NY, ⁴Medicine/Rheumatology, NYU School of Medicine/NYU Hospital for Joint Diseases, New York, NY, ⁵Radiology, NYU Langone Medical Center, New York, NY, ⁶University of Maryland School of Medicine, Baltimore, MD, USA, Baltimore, MD, ⁷Departments of Medicine and Epidemiology & Public Health, University of Maryland School of Medicine, Baltimore, MD, ⁸Department of Medicine, Duke University Medical Center, Durham, NC, ⁹Thurston Arthritis Research Center, University of North CArolina at Chapel Hill, Chapel Hill, NC, ¹⁰Dept of Rheumatology/Medicine, Hosp for Joint Diseases/NYU, New York, NY
Background/Purpose: Growing numbers of studies show increased expression in Osteoarthritis (OA) of inflammatory cytokines, such as IL-1β and TNFα, in joint tissues and peripheral blood…
Abstract Number: 58 • 2016 ACR/ARHP Annual Meeting
Detecting Novel Candidate Risk Genes in Rheumatoid Arthritis with Gene-Based Association Testing
Aleksander Lenert¹ and David Fardo², ¹Internal Medicine, Div. of Rheumatology, University of Kentucky, Lexington, KY, ²Biostatistics, College of Public Health, University of Kentucky, Lexington, KY
Background/Purpose: Rheumatoid arthritis (RA) is driven by immune-system dysfunction with contribution from genetic risk factors. Emerging data from genomewide association studies (GWAS) of single nucleotide…
Abstract Number: 59 • 2016 ACR/ARHP Annual Meeting
Novel Agents for Blocking the Interaction of Immune Complexes with the Activatory FcγRIIIa Receptor
James Robinson¹, Euan Baxter¹, Darren Tomlinson², Richard Foster³, Robin Owen⁴, Stephanie Win¹, Joanne Nettleship⁵, Christian Tiede², Jayakanth Kankanala², Raymond Owens⁵, Colin Fishwick³, Michael McPherson² and Ann Morgan⁶, ¹NIHR Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, United Kingdom, ²Astbury Centre, School of Molecular and Cellular Biology, University of Leeds, Leeds, United Kingdom, ³School of Chemistry, University of Leeds, Leeds, United Kingdom, ⁴Harwell Science and Innovation Campus, Diamond Light Source, Didcot, United Kingdom, ⁵Research Complex at Harwell, Oxford Protein Production Facility - UK, Oxford, United Kingdom, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, Great Britain
Background/Purpose: Protein-protein interactions are essential for the control of cellular functions and critical for regulation of the immune system. One example is the binding of…
Abstract Number: 60 • 2016 ACR/ARHP Annual Meeting
A Single Nucleotide Polymorphism of IL6-Receptor Is Associated with Response to Tocilizumab in Rheumatoid Arthritis: Results from Toci and ROC Studies
Cécile Luxembourger¹, Adeline Ruyssen-Witrand², Yannick Degboé³, Alain G. Cantagrel¹, Arnaud CONSTANTIN⁴, Philippe Gaudin⁵, Christian Jorgensen⁶, Jean-Francis Maillefert⁷, Hubert Marotte Sr.⁸, Delphine Nigon⁹, Daniel Wendling¹⁰, Jacques-Eric Gottenberg¹¹ and Yves-marie Pers¹², ¹Rheumatology, Centre Hospitalier Universitaire, Toulouse Purpan, Toulouse, France, ²Rheumatology Center, Purpan University Hospital, Toulouse, France, ³Rheumatology, Rheumatology Center, Purpan University Hospital, Toulouse, France, ⁴Rheumatology, CHU Purpan - Hôpital Pierre-Paul Riquet, Toulouse, France, ⁵Rheumatology, Grenoble University Hospital, France, Grenoble, France, ⁶Inserm u844, Unite ImmunoRhumatologie Therapeutique, Montpellier, France, ⁷Rheumatology, University Hospital, Dijon, France, ⁸CHU de St Etienne, Service de rhumatologie, St Etienne, France, ⁹CHU Purpan, Toulouse, France, ¹⁰Rheumatology, Besançon university hospital, Besançon, France, ¹¹Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ¹²coordination RIC SUD, Montpellier, France
Background/Purpose: Biological agents (boDMARDs) have modified the therapeutic management of patients with rheumatoid arthritis (RA). However, boDMARDs can induce sustained remission in only 30% of…
Abstract Number: 61 • 2016 ACR/ARHP Annual Meeting
Killer Immunoglobulin-like Receptors Are Associated with Ankylosing Spondylitis
Aimee Hanson¹, International Genetics of Ankylosing Spondylitis Consortium (IGAS)², Kim-Anh Lê Cao³, Tony J. Kenna⁴ and Matthew A. Brown², ¹The University of Queensland Diamantina Institute, Translational Research Instiute, Brisbane, Australia, Brisbane, Australia, ²Translational Genomics Group, Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, Australia, Brisbane, Australia, ³Translational Research Instiute, The University of Queensland Diamantina Institute, Brisbane, Australia, ⁴Translational Research Institute, Translational Genomics Group, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia
Background/Purpose: Killer immunoglobulin-like receptors (KIRs) are expressed predominantly on the surface of natural killer (NK) cells and some T-cells and are important in regulating the…
Abstract Number: 1L • 2015 ACR/ARHP Annual Meeting
Tocilizumab for the Treatment of Giant Cell Arteritis – a Randomized Placebo-Controlled Trial
Sabine Adler¹, Stephan Reichenbach², Stefan Kuchen³, Felix Wermelinger², Diana Dan², Peter M. Villiger² and Michael Seitz², ¹Rheumatology, Immunology, Allergology, University Hospital Bern, Bern, Switzerland, ²Department of Rheumatology, Immunology and Allergology, University Hospital Bern, Bern, Switzerland, ³Department of Rheumatology, Immunology and Allergology, University Hospital Bern, Bern, MD, Switzerland
Background/Purpose: Giant cell arteritis (GCA) is characterized by a destructive, granulomatous inflammation in the walls of medium and large-sized arteries. Glucocorticoid (GC) treatment controls symptoms…
Abstract Number: 2L • 2015 ACR/ARHP Annual Meeting
Baricitinib Versus Placebo or Adalimumab in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to Background Methotrexate Therapy: Results of a Phase 3 Study
Peter C. Taylor¹, Edward C. Keystone^2,3, D. van der Heijde⁴, Yoshiya Tanaka⁵, Taeko Ishii⁶, Kahaku Emoto⁶, Lili Yang⁶, Vipin Arora⁶, Carol L. Gaich⁶, Terence Rooney⁶, Douglas E. Schlichting⁶, William Macias⁶, Stephanie de Bono⁶ and Michael E. Weinblatt⁷, ¹Nuffield Dept. of Orthopaedics, Rheumatology and Musculoskeletal, Sciences, Kennedy Institute of Rheumatology, University of Oxford,, Oxford, United Kingdom, ²University of Toronto, Toronto, ON, Canada, ³Rebecca MacDonald Centre, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵The First Dept. of Internal Medicine, University of Occupational & Environmental Health, Kitakyusyu, Japan, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Brigham and Women’s Hospital, Boston, MA
Background/Purpose: In phase 3 studies, baricitinib (bari) improved disease activity in patients (pts) with active RA and an inadequate response (IR) to conventional synthetic DMARDs1…
Abstract Number: 3L • 2015 ACR/ARHP Annual Meeting
A Randomised Controlled Trial of the Clinical Effectiveness, Safety and Cost-Effectiveness of Adalimumab in Combination with Methotrexate for the Treatment of Juvenile Idiopathic Arthritis Associated Uveitis
Athimalaipet V Ramanan¹, Andrew D. Dick², Andrew McKay³, Ashley Jones⁴, Paula Williamson⁴, Sandrine Compeyrot-Lacassagne⁵, Ben Hardwick⁴, Helen Hickey⁴, Dyfrig Hughes⁶, Patricia Woo⁵, Diana Benton¹, Clive Edelsten⁵ and Michael W. Beresford⁷, ¹University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom, ²University of Bristol, Bristol Eye Hospital, Bristol, United Kingdom, ³Biostatistics, Clinical Trials Research Centre, University of Liverpool, Liverpool, United Kingdom, ⁴Clinical Trials Research Centre, University of Liverpool, Liverpool, United Kingdom, ⁵Great Ormond Street Hospital, London, United Kingdom, ⁶Bangor University, Bangor, United Kingdom, ⁷University of Liverpool, Liverpool, United Kingdom
Background/Purpose: Uveitis associated with Juvenile Idiopathic Arthritis (JIA) is a major cause of morbidity with potentially sight-threatening complications. Despite current screening and (pre-biologic) therapeutic options,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].